CCX 140

Drug Profile

CCX 140

Alternative Names: CCX-140B; CCX140

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Vifor
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Preclinical Focal segmental glomerulosclerosis
  • Research Kidney disorders
  • No development reported Type 2 diabetes mellitus
  • Discontinued Multiple sclerosis; Vascular restenosis

Most Recent Events

  • 07 Nov 2017 ChemoCentryx plans a registration-supporting trial for Focal segmental glomerulosclerosis in Q4 2017
  • 31 Mar 2017 ChemoCentryx has patent protection for CCX 140 in USA, Europe, Japan, Australia, Canada, China, Israel, Mexico and Hong Kong
  • 31 Mar 2017 ChemoCentryx has patents pending for CCX 140 in India, South Korea and Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top